Related Experiment Video
Updated: Jul 17, 2026
07:00
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
Review article: glucagon-like peptide 2--current applications and future directions
K Wallis1, J R F Walters, A Forbes
1Division of Medicine, Imperial College, Hammersmith Hospital, London, UK.
Alimentary Pharmacology & Therapeutics
|January 16, 2007
Summary
Glucagon-like peptide 2 (GLP-2) enhances gut health and shows therapeutic potential for short bowel syndrome and Crohn's disease. Further research into its bone metabolism effects and long-term safety is warranted.
Area of Science:
- Gastroenterology
- Endocrinology
- Molecular Biology
Background:
- Glucagon-like peptide 2 (GLP-2) is an intestinal peptide growth factor.
- GLP-2 specifically regulates gut mucosal morphology, function, and integrity.
Purpose of the Study:
- To review the molecular biology, mechanisms of action, and physiological properties of GLP-2.
- To discuss recent clinical data on GLP-2 as a therapeutic agent.
Main Methods:
- Literature search using Medline.
- Review of reference lists from key publications.
Main Results:
- GLP-2 is effective in improving fluid absorption in short bowel syndrome.
- GLP-2 demonstrates superiority over placebo in inducing remission for Crohn's disease.
- Emerging data suggest GLP-2 may offer a new treatment for osteoporosis via bone metabolism effects.
Conclusions:
- GLP-2 shows promise for treating various gastrointestinal injuries by improving barrier function and mucosal healing.
- Long-term use of GLP-2 requires careful consideration of safety aspects due to its potent growth-promoting nature.
More Related Videos
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.